Women in Biotech: NextRNA CEO Dominique Verhelle - GBH News
external-link
Bayer partners with NextRNA to develop lncRNA-targeting cancer therapies - Pharmaceutical Business Review
external-link
Bayer teams up with lncRNA-focused NextRNA in $547m deal - Pharmaceutical Technology
external-link
Long non-coding RNAs: what’s behind the growing “dark genome” buzz? - Labiotech.eu
external-link
September 26 2024
NextRNA Therapeutics Expands Executive Team with Appointment of Jesse Smith, PhD as Chief Scientific Officer
More
external-link
Our CEO Dominique Verhelle participated in a panel discussion yesterday focused on non-coding RNA (ncRNA) and epigenetics at the #DarkGenomeSymposium in NYC. Dominique shared NextRNA's therapeutic app
external-link
Our Co-Founder & CEO, Dominique Verhelle, will give a corporate presentation on Monday, Sep. 30th at 1:30 pm ET at Chardan’s 8th Annual Genetic Medicines Conference in NYC.
There is increasing evide
external-link
Bayer and NextRNA Therapeutics enter oncology partnership worth $547m - PMLiVE
external-link
NextRNA Therapeutics Strengthens Board of Directors with Appointment of Lori Friedman, PhD - Business Wire
external-link
August 28 2024
Bayer partners with RNA drugmaker to develop new cancer therapies
BioPharma Dive
external-link
Our team recently set sail for an unforgettable team-building adventure in Newport, RI, where we raced 12-meter America's Cup sailboats! It was not only an amazing experience navigating the open water
external-link
March 01 2022
NextRNA Launches with $56 Million in Funding to Bring Transformative Non-coding RNA-directed Medicines to Patients
More
external-link
Bayer, NextRNA to Develop Therapeutics Targeting Oncology - Yahoo Finance
external-link
August 28 2024
Boston biotech signs deal with Bayer worth up to $547 million
Boston Business Journal
external-link
NextRNA Therapeutics Appoints Charles Kunsch, Ph.D. to Board of Directors
external-link
NextRNA Launches with $56 Million in Funding to Bring Transformative Non-Coding RNA-Directed Medicines to Patients - Business Wire
external-link
Bayer pens $547M biobucks pact with biotech pushing the boundaries of noncoding RNA - Fierce Biotech
external-link
NextRNA Therapeutics Appoints Seasoned Industry Leader Charles Kunsch, Ph.D. to Board of Directors - Business Wire
external-link
Bayer inks deal with NextRNA on IncRNA-driven diseases - The Pharma Letter
external-link
A new biotech out of Dana-Farber wants to join the long non-coding RNA party, with help from Bob Langer - Endpoints News
external-link
I look forward to participating in this partnership-focused panel at the Longwood Healthcare Leaders Boston CEO forum next week to discuss how NextRNA and Bayer's collaboration is reflective of each o
external-link
Fenwick Represents NextRNA Therapeutics in Strategic Collaboration with Bayer - Fenwick & West LLP
external-link
September 22 2022
NextRNA Therapeutics to Participate in Upcoming BioPharm America and Chardan’s 6th Annual Genetic Medicines Conference
M
external-link
At NextRNA, we believe in the power of community and the importance of supporting and empowering women. Recently, a group of our amazing employees had the honor of volunteering at Rosie's Place, a san
external-link
August 28 2024
Bayer pens $547M biobucks pact with biotech pushing the boundaries of noncoding RNA FierceBiotech
Fierc
external-link
September 04 2024
Bayer and NextRNA sign $500M+ lncRNA oncology deal
Inside Precision Medicine
external-link
Our Co-Founder and CEO, Dominique Verhelle, will participate in a panel on Oct. 28 at 4:10pm at the Longwood Healthcare Leaders Boston CEO forum, titled "Aligning Priorities for the Partnership." As p
external-link
The ‘Junk’ Genome May Actually Unlock The Next Cancer Treatment
external-link
Bayer and NextRNA: One partnership, two oncology programs - BioXconomy
external-link
Bayer and NextRNA Sign $500M+ IncRNA Oncology Deal - Inside Precision Medicine
external-link
NextRNA Therapeutics on LinkedIn: #bio2024 #rna #ncrna #lncrna #bio24 #cancer #oncology…
external-link
August 28 2024
Bayer and NextRNA Therapeutics enter strategic collaboration to develop small molecules targeting long non-coding RNAs (lncRNAs) in
external-link
June 21 2023
The Long and Short of It: Exploring the Therapeutic Potential of lncRNAs
Q&A with Susan Carpenter, PhD
Associate Professor of M
external-link
October 23 2024
The ‘Junk’ Genome May Actually Unlock The Next Cancer Treatment
Forbes
More
external-link
NextRNA Therapeutics Names Dominique Verhelle as CEO and Expands Leadership Team
external-link
We’re excited to announce that Charles Kunsch has been appointed to our Board of Directors!
Read the press release: https://bit.ly/4fkC2Jj
Currently a Venture Partner at Dreavent Capital and previo
external-link
September 10 2024
Long non-coding RNAs: what’s behind the growing “dark genome” buzz?
Labiotech.eu
external-link
Boston biotech signs deal with Bayer worth up to $547M - The Business Journals
external-link
We’re excited to announce the appointment of Jesse Smith as NextRNA’s Chief Scientific Officer! With his deep expertise in pioneering first-in-class targeted small molecule therapies, Dr. Smith is ide
external-link
August 28 2024
Bayer signs $547 million pact with NextRNA in oncology push
Bloomberg
More
external-link
Bayer partners with RNA drugmaker to develop new cancer therapies - BioPharma Dive
external-link
December 08 2022
NextRNA Therapeutics to Participate in Upcoming 5th Annual RNA-Targeted Drug Discovery Summit
More
external-link
Bayer partners with RNA startup launched out of Dana-Farber - Endpoints News
external-link
September 26 2023
NextRNA Therapeutics Strengthens Board of Directors with Appointment of Lori Friedman, PhD
More
external-link
June 06 2023
The Long and Short of It: Exploring the Therapeutic Potential of lncRNAs
Q&A with John Mattick, PhD
Professor of RNA Biology at
external-link
Bayer signs $547 million pact with Boston-based NextRNA in oncology push - The Boston Globe
external-link
Bayer Signs $547 Million Pact With NextRNA in Oncology Push - Bloomberg
external-link
August 28 2024
Bayer partners with NextRNA on lncRNA-targeted small molecules for cancer
FirstWord Pharma
external-link
NextRNA Therapeutics Raises $56M in Seed and Series A Funding
external-link
Lilly taps RNA biotech for $1 billion weight-loss collaboration - Chemical & Engineering News
external-link
Bayer and NextRNA Therapeutics Enter Strategic Collaboration to Develop Small Molecules Targeting Long Non-Coding RNAs (lncRNAs) in Oncology - Business Wire
external-link
Bayer and NextRNA Therapeutics Enter Strategic Collaboration to Develop Small Molecules Targeting Long Non-Coding RNAs (lncRNAs) in Oncology
external-link
July 10 2023
The Long and Short of It: Exploring the Therapeutic Potential of lncRNAs
Q&A with Rory Johnson, PhD
Associate Professor, Univer
external-link
August 11 2022
NextRNA Therapeutics names Dominique Verhelle as CEO and expands leadership team
More
external-link
December 12 2024
NextRNA Therapeutics Appoints Seasoned Industry Leader Charles Kunsch, Ph.D. to Board of Directors
More
external-link
NextRNA Therapeutics Expands Executive Team with Appointment of Jesse Smith, PhD as Chief Scientific Officer
external-link